Clinical trial · Observational
A Trial to Evaluate the Superior Mesenteric Vein (14V) Lymphadenectomy for Distal Advanced Gastric Cancer
Randomized Controlled Trial to Evaluate Mesenteric Vein (14V) Lymphadenectomy for Gastric Cancer
NCT02272894CI-TRIAL-00020121unknownClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This trial is going to evaluate the advantage of D2 radical gastrectomy plus 14v lymph node dissection in 3-year survival rates of advanced gastric cancers.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Gastric Cancer | Malignant Gastric Neoplasm | CURATED_BROADER | 0.80 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Dissection of the Superior Mesenteric Vein Lymph Node | Procedure | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- label
- Group A
- description
- D2 Radical Gastrectomy Adding Dissection of the Superior Mesenteric Vein Lymph Node
- interventionNames
- Procedure: Dissection of the Superior Mesenteric Vein Lymph Node
- label
- Group B
- description
- D2 Radical Gastrectomy
Primary outcomes (1)
- measure
- overall survival
- timeFrame
- 3 years
- description
- Overall survival (OS) was defined as the length of time from the date of randomization to the date of death of various reasons.
Secondary outcomes (1)
- measure
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 70 Years
Show eligibility criteria text
Inclusion Criteria: * Curative D2 or D2+ operation had been performed; * Physical condition and organ function allows to tolerable abdominal surgery; * Willing and able to comply with the program during the study period; * Aged 18 to 70 years, preoperative gastric cancer patients with pathologically confirmed; * With more than a 6-month life expectancy; * No other serious concomitant diseases; * No adjuvant chemotherapy before recurrence; * Karnofsky performance status scale ≥ 60; * All patients accept 6 cycles XELOX chemotherapy regimen Exclusion Criteria: * Pregnancy or breast feeding; * Women of childbearing age do not take contraceptive measures; * Organ transplantation patients need immunosuppressive therapy; * Five years after the trial begin,other malignant tumor occur; * While using other experimental drug or other clinical trials are being; * Can not take oral medications; * Mentally disordered; * Severe recurrent infections were not controlled or with other serious concomitant diseases;
References
Publications (1)
- DERIVEDYang QC, Zhou HK, Yue C, Wang WD, Gao RQ, Mo ZC, Ji PP, Wei JP, Yang XS, Yu PF, Li XH, Ji G. [The correlation between No. 6 and No. 14v lymph node metastasis and the value of dissecting these lymph nodes in radical gastrectomy]. Zhonghua Wei Chang Wai Ke Za Zhi. 2023 Jan 25;26(1):38-43. doi: 10.3760/cma.j.cn441530-20221123-00491. Chinese. PMID 36649998